Adam Kittai
Overview
Explore the profile of Adam Kittai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soumerai J, Barrientos J, Barrientos J, Ahn I, Ahn I, Coombs C, et al.
Blood Adv
. 2024 Nov;
9(5):1213-1229.
PMID: 39561376
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are...
2.
Herbst S, Vesterlund M, Helmboldt A, Jafari R, Siavelis I, Stahl M, et al.
Nat Commun
. 2022 Oct;
13(1):6226.
PMID: 36266272
Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains...
3.
Bhat S, Gambril J, Azali L, Chen S, Rosen L, Palettas M, et al.
Blood
. 2022 Aug;
140(20):2142-2145.
PMID: 35917449
Acalabrutinib, a next-generation Bruton's tyrosine kinase inhibitor (BTKi), associates with dramatic efficacy against B-cell malignancies. Recently, unexplained ventricular arrhythmias (VAs) with next-generation BTKi-therapy have been reported. Yet, whether acalabrutinib associates...
4.
Chen S, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, et al.
J Hematol Oncol
. 2022 Jul;
15(1):92.
PMID: 35836241
Background: Post-market analyses revealed unanticipated links between first-generation Bruton's tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi...
5.
Schaefer A, Huang Y, Kittai A, Maakaron J, Saygin C, Brammer J, et al.
Cancer Manag Res
. 2021 Dec;
13:8901-8906.
PMID: 34876852
Introduction: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes....
6.
Lam V, Best S, Kittai A, Orand K, Spurgeon S, Liu T, et al.
Br J Clin Pharmacol
. 2021 Jul;
88(2):836-841.
PMID: 34196037
Spleen tyrosine kinase (SYK) is indispensable in B-cell receptor signalling. SYK inhibitor entospletinib demonstrated clinical efficacy in patients with chronic lymphocytic leukaemia (CLL). However, pharmacodynamic effects of SYK inhibition in...
7.
Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova O, et al.
Leukemia
. 2020 Mar;
35(1):156-168.
PMID: 32203139
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as...
8.
Best S, Liu T, Bruss N, Kittai A, Berger A, Danilov A
Leuk Lymphoma
. 2019 May;
60(12):2946-2950.
PMID: 31111763
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and...
9.
Best S, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, et al.
Blood Adv
. 2019 Jan;
3(1):51-62.
PMID: 30617217
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin...
10.
Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock S, et al.
Cancer
. 2018 May;
124(15):3192-3200.
PMID: 29797667
Background: Most patients with chronic lymphocytic leukemia (CLL) present with multiple comorbidities. Although comorbidities negatively affect outcomes for patients treated with chemoimmunotherapy, their impact on patients who receive targeted therapies...